Clinical Trial

START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC

Study acronym: START-MET
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 19, 2023 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.
Summary
Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients and second generation hormonal treatments (Apalutamide/Abiraterone+Prednisone/Enzalutamide) vs androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients plus second generation hormonal treatments, for the treatment of oligometastatic prostate cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-01-25; most recent amendment 2023-05-18.
Status change: Not Yet Recruiting → Recruiting 2023-03-02
Trial Details
NCT Number NCT05209243
Lead Sponsor Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Conditions Prostate Cancer, Stereotactic Body Radiation Therapy
Enrollment 266 participants
Start Date 2023-01-26
Primary Completion 2025-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2023-05-19